<DOC>
	<DOC>NCT00666029</DOC>
	<brief_summary>To characterize features of metabolic syndrome in volunteers. To undertake a randomised trial to determine whether treatment with a statin improves muscle microvascular blood flow.</brief_summary>
	<brief_title>Implications for Treatment of the Metabolic Syndrome</brief_title>
	<detailed_description>To characterise features of the metabolic syndrome, including body fat, insulin sensitivity, and liver fat together with muscle micorvascular blood flow. To undertake a randomised controlled trial of atorvastatin 40 mg. o.d for 6 months to determine whether any of the above measures change with treatment.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Body mass index (BMI) 2035 kg/m^2" and "&gt; 3 criteria for the metabolic syndrome , one of which will be hypertriglyceridaemia, i.e. fasting plasma triglycerides &gt;2.0 mmol/L a cardinal lipid abnormality of the syndrome NCEP III ATP metabolic syndrome criteria are: Waist greater than or equal to 102 cm BP greater than 130 / 85 TG greater than or equal to 1.7mmol/l Glucose greater than or equal to 6.1 mmol/l HDL less than 1.0 mmol/l Aged &lt;18 years &gt;75 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>Volunteers recruited from the community</keyword>
</DOC>